Cat Allergy - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 38 pages report, published by Global Markets Direct

Keywords : Cat Allergy Therapeutic Products under Development, Key Players in Cat Allergy Therapeutics, Cat Allergy Pipeline Overview, Cat Allergy Pipeline, Cat Allergy Pipeline Assessment

Report ThumbnailSeptember-2013
Cat Allergy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cat Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cat Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cat Allergy. Cat Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cat Allergy.
- A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cat Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cat Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Cat Allergy, H2 2013 7
  • Products under Development for Cat Allergy - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Discovery and Pre-Clinical Stage Products, H2 2013 11
  • Assessment by Monotherapy Products, H2 2013 16
  • Assessment by Route of Administration, H2 2013 17
  • Assessment by Stage and Route of Administration, H2 2013 18
  • Assessment by Molecule Type, H2 2013 19
  • Assessment by Stage and Molecule Type, H2 2013 20
  • List of Tables
  • Number of Products Under Development for Cat Allergy, H2 2013 7
  • Products under Development for Cat Allergy - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • ALK-Abello A/S, H2 2013 13
  • Circassia Holdings Ltd., H2 2013 14
  • Biomay AG, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 16
  • Assessment by Stage and Route of Administration, H2 2013 18
  • Assessment by Stage and Molecule Type, H2 2013 20
  • Cat Allergy Therapeutics - Drug Profile Updates 28
  • Cat Allergy Therapeutics - Discontinued Products 30
  • Cat Allergy Therapeutics - Dormant Products 31
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Cat Allergy Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Cat Allergy 7
  • Cat Allergy Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Discovery and Pre-Clinical Stage Products 11
  • Comparative Analysis 11
  • Cat Allergy Therapeutics - Products under Development by Companies 12
  • Companies Involved in Cat Allergy Therapeutics Development 13
  • ALK-Abello A/S 13
  • Circassia Holdings Ltd. 14
  • Biomay AG 15
  • Cat Allergy - Therapeutics Assessment 16
  • Assessment by Monotherapy Products 16
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 19
  • Drug Profiles 21
  • Cat-SPIRE - Drug Profile 21
  • Product Description 21
  • Mechanism of Action 21
  • R&D Progress 21
  • ALK Recombinant Cat Vaccine - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • Cat Allergen Peptide Carrier Fusion Vaccine - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • Cat Allergen Vaccine - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Cat Allergy Therapeutics - Drug Profile Updates 28
  • Cat Allergy Therapeutics - Discontinued Products 30
  • Cat Allergy Therapeutics - Dormant Products 31
  • Cat Allergy - Product Development Milestones 32
  • Featured News & Press Releases 32
  • Feb 25, 2013: Circassia’s ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy 32
  • Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 32
  • Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology 33
  • Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 34
  • Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 34
  • Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 35
  • Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 36
  • Appendix 37
  • Methodology 37
  • Coverage 37
  • Secondary Research 37
  • Primary Research 37
  • Expert Panel Validation 37
  • Contact Us 38
  • Disclaimer 38

Please select a license type

Share

Related Products

Global Markets DirectCat Allergy - Pipeline Review, H2 2013Product ThumbnailCat Allergy - Pipeline Review, H2 2013, Industry ReportProduct #: 113347
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved